Endocrinology and metabolism clinics of North America

• 

  Año 2026, Vol. 55, Número 3. Texto Completo Ejemplar

  • Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation

    Courtney A. Ackeifi, Manish N. Shah

    • Resumen
    • Texto completo

    págs. 15-19

    

  • Beyond Insulin: Why Type 1 Diabetes Mellitus Needs More?

    Fan Huaying, L. Snaith, Jerry R. Greenfield

    • Resumen
    • Texto completo

    págs. 379-393

    

  • Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1

    María de las Aguas Robustillo Cortés, Phoom Narongkiatikhun, L. F. Fehri, Darwin Castillo-Benites, Kalie L. Tommerdahl, Alexandra Nadeau, Petter Bjornstad

    • Resumen
    • Texto completo

    págs. 395-405

    

  • Beyond Glycemia in T1D: Insulin Resistance and Multiorgan Injury in Type 1 Diabetes-Part 2

    María de las Aguas Robustillo Cortés, Phoom Narongkiatikhun, Coco Fuhri Snethlage, Darwin Castillo-Benites, Kalie L. Tommerdahl, Alexandra Nadeau, Petter Bjornstad

    • Resumen
    • Texto completo

    págs. 407-419

    

  • Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we’ve Learned and What Comes Next

    Rachael Innes, J. Petrie, Thomas Fremming Dejgaard

    • Resumen
    • Texto completo

    págs. 421-435

    

  • Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes: What We Know So Far and Future Trials

    Amelia Cristina Stein, Meghan Pauley, Janet K. Snell-Bergeon

    • Resumen
    • Texto completo

    págs. 437-453

    

  • GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes

    Justin P.J

    • Resumen
    • Texto completo

    págs. 455-466

    

  • Current State of Cardiorenal Disease in People with Type 1 Diabetes

    Stuti Fernandes, Barbara Hettinger, Angela Glynn, Rodica Pop Busui

    • Resumen
    • Texto completo

    págs. 467-476

    

  • Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes

    Stuti Fernandes, Barbara Hettinger, Angela Glynn, Rodica Pop Busui

    • Resumen
    • Texto completo

    págs. 477-493

    

  • Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes

    Michael Hughes, Francisco J. Pasquel

    • Resumen
    • Texto completo

    págs. 495-514

    

  • Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes

    Halis Kaan Akturk

    • Resumen
    • Texto completo

    págs. 515-524

    

  • Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes

    A. Saeed, Manish N. Shah

    • Resumen
    • Texto completo

    págs. 525-536

    

  • Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes

    Jayachidambaram Ambalavanan, Kanchan Bhasin, Manish N. Shah

    • Resumen
    • Texto completo

    págs. 537-546

    

  • Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents

    Husam Ghanim, Sambasiva Rao Srungavarapu, Paresh Dandona, Ajay Chaudhuri

    • Resumen
    • Texto completo

    págs. 547-561

    

  • Expectations and Experiences: What People with Type 1 Diabetes Really Want from Adjunctive Therapies

    Julian A. Feller

    • Resumen
    • Texto completo

    págs. 563-572

    

  • The Horizon Ahead: Emerging Adjunctive Therapies for Type 1 Diabetes

    Hela Ben Hamida, Jeremy M. Henley

    • Resumen
    • Texto completo

    págs. 573-580